|
A recombinant hepatitis B vaccine that integrates the S, pre-S1, and pre-S2 surface proteins of the hepatitis B virus. Enables successful immunization with significantly lower doses of vaccine than other recombinant hepatitis B vaccines. Licensed to Bio-Technology General, Inc., a subsidiary of Ferring Inc. Bio-Hep-B is marketed in Israel and registrations in other countries are under way.
|
|
The first innovative drug to be developed in Israel and to receive FDA approval, Copaxone® is a unique multiple sclerosis immunomodulator: the first and only non-interferon agent for the treatment of relapsing-remitting multiple sclerosis. Copaxone® is licensed to Teva Pharmaceuticals Ltd.
Read more >>
|
|
(Beta-carotene), a health food product with possible anti-cancer properties, extracted from Dunaliella, a local alga, licensed to Nikken Sohonsha Corporation.
Read more >>
|
|
This algorithm is licensed to NDS Ltd., and is widely used as the basis for television set-top box smart cards. To date, over 50 million smart cards are in use throughout the world.
Read more >>
|
|
An antibody based therapy presenting synergism with conventional chemotherapy. The synergistic effect was invented at the Weizmann Institute. Erbitux was developed by ImClone Systems and approved by the FDA in 2001.Imclone has a license to the synergism patent. Erbitux Sales in 2007 exceeded 1B$.
Read more >>
|
|